Skip to content
Triangle logo TriangleGet started
← Full study record

NCT06099782 · OUTCOME

Percentage of Participants Who Chose Pembrolizumab (+) Berahyaluronidase Alfa SC or Pembrolizumab IV for the Treatment Continuation Period on the Participant Choice Questionnaire

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) · Source last updated 2026-04-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of Participants
Interval / dispersion
Not reported
Time frame
Day 106

What was measured

The Participant Choice Questionnaire offered participants SC or IV treatment administration choices for the Treatment Continuation Period of the study, and was administered on Day 106 after study intervention administration. As pre-specified by the sSAP, the percentage of participants who chose either SC or IV treatment for the Treatment Continuation Period in the study was reported out of all randomized participants who chose to receive treatment intervention in the Treatment Continuation Period.

Analysis population: The analysis population included all randomized participants who chose to receive treatment intervention in the Treatment Continuation Period via the Participant Choice Questionnaire. Six participants included in the analysis chose to receive treatment in the Treatment Continuation Period but discontinued before receiving actual treatment.

Groups in this outcome

Participants Continuing Treatment in Continuation Period

Randomized participants received three doses of pembrolizumab plus berahyaluronidase alfa SC and three doses of pembrolizumab IV during the Treatment Crossover Period and subsequently chose to receive treatment in the Treatment Continuation Period via the Participant Choice Questionnaire.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Participants Continuing Treatment in Continuation Period122

Reported measurements

SC
Values in Percentage of Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Participants Continuing Treatment in Continuation Period68.0Not reportedNot reportedNot reportedNot reported
IV
Values in Percentage of Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Participants Continuing Treatment in Continuation Period32.0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        68.0
    title
    SC
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        32.0
    title
    IV
denoms
  1. counts
    1. group Id
      OG000
      value
      122
    units
    Participants
description
The Participant Choice Questionnaire offered participants SC or IV treatment administration choices for the Treatment Continuation Period of the study, and was administered on Day 106 after study intervention administration. As pre-specified by the sSAP, the percentage of participants who chose either SC or IV treatment for the Treatment Continuation Period in the study was reported out of all randomized participants who chose to receive treatment intervention in the Treatment Continuation Period.
groups
  1. description
    Randomized participants received three doses of pembrolizumab plus berahyaluronidase alfa SC and three doses of pembrolizumab IV during the Treatment Crossover Period and subsequently chose to receive treatment in the Treatment Continuation Period via the Participant Choice Questionnaire.
    id
    OG000
    title
    Participants Continuing Treatment in Continuation Period
param Type
NUMBER
population Description
The analysis population included all randomized participants who chose to receive treatment intervention in the Treatment Continuation Period via the Participant Choice Questionnaire. Six participants included in the analysis chose to receive treatment in the Treatment Continuation Period but discontinued before receiving actual treatment.
reporting Status
POSTED
time Frame
Day 106
title
Percentage of Participants Who Chose Pembrolizumab (+) Berahyaluronidase Alfa SC or Pembrolizumab IV for the Treatment Continuation Period on the Participant Choice Questionnaire
type
SECONDARY
unit Of Measure
Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice